NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo. Safety data showed that both evaluated doses of abrocitinib (200mg and 100mg) were well tolerated and were consistent with a companion study (JADE MONO-2) from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program. The results were shared as a Late-Breaking presentation at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) taking place October 9-13, 2019 in Madrid, Spain.
The co-primary study endpoints in JADE MONO-1 were the proportion of patients who achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin and two-point or greater improvement relative to baseline; and the proportion of patients who achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score. The key secondary endpoints were the proportion of patients achieving a four-point or larger reduction in itch severity measured with the pruritus numerical rating scale (NRS), and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), a patient-reported measurement scale developed by Pfizer. Other secondary endpoints included the proportion of patients who achieved a 90% or greater change in EASI score, and the percentage change from baseline in their SCORing Atopic Dermatitis (SCORAD) response at all scheduled time points.
There is a critical need for additional treatment options for patients living with moderate to severe atopic dermatitis, said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase 3 trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients.
JADE MONO-1 Study Efficacy Results1
Both doses of abrocitinib significantly improved the IGA and EASI-75 dose response outcomes compared to placebo. By week 12, the following co-primary efficacy and secondary endpoint results were seen:
Abrocitinib200mg (N=154)
Abrocitinib100mg (N=156)
Placebo (N=77)
IGA Response Rate
43.8%
23.7%
7.9%
EASI-75 Response Rate
62.7%
39.7%
11.8%
NRS 4-Point Improvement Response Rate
57.2%
37.7%
15.3%
EASI-90 Response Rate
38.6%
18.6%
5.3%
The percentage changes in SCORAD were significantly greater at all time points in the 200mg and 100mg treatment arms compared to placebo.
JADE MONO-1 Safety Results1
The most frequently reported treatment-emergent adverse events in abrocitinib-treated patients (200mg, 100mg) were short-lasting nausea (20.1%, 9.0%), headache (9.7%, 7.7%), and nasopharyngitis (11.7%, 14.7%), while for placebo, it was dermatitis (16.9%). Observed serious adverse events (SAEs) for abrocitinib 200mg were inflammatory bowel disease, peritonsillitis, dehydration, and asthma (2 cases). SAEs seen for the 100mg dose included retinal detachment, acute pancreatitis, appendicitis, dizziness, and seizures. In the placebo arm, SAEs were condition aggravated, appendicitis, meniscal degeneration, and atopic dermatitis. Other safety findings included:
Abrocitinib200mg (N=154)
Abrocitinib100mg (N=156)
Placebo (N=77)
Rate of Serious Adverse Events
3.2%
3.2%
1.9%
Rate of Discontinuation due to an Adverse Event
5.8%
5.8%
9.1%
Additional Details About the JADE MONO-1 Study
The double-blind, parallel group study randomized a total of 387 subjects to abrocitinib 200mg, abrocitinib 100mg, or placebo. Randomization was stratified by baseline disease severity (moderate [IGA=3] and severe [IGA=4] AD) and age (age <18 and 18 years). Eligible subjects completing the 12-week treatment period of the study had the option to enter a long-term extension (LTE) study, B7451015. Subjects discontinuing early from treatment, or who were otherwise ineligible for the LTE study, entered a 4-week follow up period in this study.
For additional information about the JADE MONO-1 study, please visit https://www.clinicaltrials.gov.
Pfizer recently announced positive top-line results from the companion Phase 3 study from the JADE program (JADE MONO-2), suggesting similar positive safety and efficacy results. Additional data for abrocitinib and new findings from the JADE program will be shared in early 2020.
Phase 2b data for abrocitinib were recently published in JAMA Dermatology.
About Abrocitinib
Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, and interferon gamma.
Abrocitinib received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate to severe AD in February 2018. Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012. As defined by the FDA, a breakthrough therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.2
About Atopic Dermatitis
AD is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.3,4 Lesions of AD are characterized by erythema (redness), itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting.3,4
AD is one of the most common, chronic, relapsing childhood dermatoses, affecting up to 10% of adults and up to 20% of children worldwide.5,6
About Pfizers Immunokinase Inhibitor Leadership
The JAK pathways are believed to play an important role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors, many of which drive immune-mediated conditions.7 JAK inhibition may offer patients with these conditions a potential new advanced treatment option.8
Pfizers leading JAK biology and chemistry expertise from years of JAK research experience, has enabled the company to take a different R&D approach, resulting in the broadest immunokinase inhibitor pipeline. Instead of studying a single molecule for all its potential uses, where it may not be optimal for some, Pfizers candidates are purposefully matched to the conditions where we believe they have the greatest potential to, if approved, address unmet need. Pfizer has five unique immunokinase inhibitors in late-stage clinical trials for the potential treatment of nine immune-mediated diseases:
Pfizer Inc.: Breakthroughs that Change Patients Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.pfizer.com. In addition, to learn more, please visit us on http://www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of October 12, 2019. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about a product candidate, abrocitinib, and Pfizers ongoing investigational programs in kinase inhibitor therapies, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for abrocitinib or any other investigational kinase inhibitor therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether abrocitinib or any such other investigational kinase inhibitor therapies will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of abrocitinib or any other investigational kinase inhibitor therapies; and competitive developments.
A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.
______________________________
1 Simpson E, Sinclair R, Forman S et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Phase 3, JADE MONO-1 Study. Oral presentation at the 28th Congress of the European Academy of Dermatology and Venereology (EADV), October 9-13, 2019, Madrid, Spain2 U.S. Food and Drug Administration. Fact Sheet: Breakthrough Therapies at https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantA... (link is external) accessed on August 16, 2019.3 Hanifin JM, Reed ML. A population-based survey of eczema in the United States. Dermatitis. 2007;18(2):82-91.4 Bieber T. Atopic dermatitis. Dermatology. 2012;1(3):203-217.5 Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015:32(6):409-420.6 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.7 Banerjee, S, Biehl, A, Gadina, M et al. JAKSTAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77: 521. https://doi.org/10.1007/s40265-017-0701-9.8 Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):344251. doi:10.1021/acschembio.6b00677.
Go here to see the original:
Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to...
- Retrospective analysis of 397 DABE | CCID - Dove Medical Press - December 3rd, 2023 [December 3rd, 2023]
- Derm In The News: November 26-December 2 - Dermatology Times - December 3rd, 2023 [December 3rd, 2023]
- When is the Best Time to Try Alternative Treatments for Eczema? - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- How Eczema Negatively Impacted the Way She Talked to Herself - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Combination Treatments in HS Require Further Review - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Addressing Misconceptions, Concerns Around Biosimilar Use - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Native American and Indigenous Communities Face Dermatologic ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Microwave Therapy Successful for Treating Warts in Children - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- 9 Best Antifungal Body Washes Review - The Jerusalem Post - September 23rd, 2023 [September 23rd, 2023]
- Patients With Severe Psoriasis Have Higher Risk of Heart Disease ... - AJMC.com Managed Markets Network - September 23rd, 2023 [September 23rd, 2023]
- Swimming and skin: What to know if a child has eczema - Harvard Health - May 20th, 2023 [May 20th, 2023]
- Experts demand traffic-light labels to show strength of eczema cream - Daily Mail - May 20th, 2023 [May 20th, 2023]
- Its mosquito season. Here are tips for treating bites, preventing them in the first place - Yahoo News - May 20th, 2023 [May 20th, 2023]
- How new EU incentives will help all patients get the best treatments - Euronews - May 20th, 2023 [May 20th, 2023]
- Consistent Use of Ceramide-Containing Products Combined With ... - Dermatology Times - May 20th, 2023 [May 20th, 2023]
- The Best Swimming Skin and Hair Products | livestrong - Livestrong - May 20th, 2023 [May 20th, 2023]
- These 13 Household Items Contain Smells That Are Harmful To ... - Rock 92.9 - May 20th, 2023 [May 20th, 2023]
- FDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease - HealthDay News - May 20th, 2023 [May 20th, 2023]
- Feds investigating eczema cream after two Oregon babies found with high levels of lead in blood - OregonLive - January 27th, 2023 [January 27th, 2023]
- Heres how to treat eczema and other skin conditions for cold weather - The Hindu - January 27th, 2023 [January 27th, 2023]
- Atopic eczema - NHS - November 23rd, 2022 [November 23rd, 2022]
- Seborrheic dermatitis - Symptoms and causes - Mayo Clinic - November 23rd, 2022 [November 23rd, 2022]
- Oatmeal skincare is the perfect solution for sensitive skin (+ best products to try) - Lifestyle Asia Singapore - November 23rd, 2022 [November 23rd, 2022]
- Eczema - StatPearls - NCBI Bookshelf - October 21st, 2022 [October 21st, 2022]
- Cold, dry weather can trigger eczema - how to reduce damage to the skin this winter - Express - October 21st, 2022 [October 21st, 2022]
- Eczema on lips nhs - kved.erxe.de - August 29th, 2022 [August 29th, 2022]
- xrfkc.vitalhaskap.pl - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - cyasn.kugel-lernfoerderung.de - August 29th, 2022 [August 29th, 2022]
- north shore zipline oahu - owk.tophouse.shop - August 29th, 2022 [August 29th, 2022]
- nak stock - vbi.maxense.shop - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - zayqif.hydra-market.shop - August 29th, 2022 [August 29th, 2022]
- fort worth map with zip codes - prxrzj.rids-gear.shop - August 29th, 2022 [August 29th, 2022]
- Ear Eczema: Symptoms, Causes, and Treatments - Healthgrades - August 29th, 2022 [August 29th, 2022]
- The Mutha Body Oil Is Worth the Splurge, Especially If You Have Sensitive Skin - POPSUGAR - August 29th, 2022 [August 29th, 2022]
- Are You Allergic to Your Beauty Products? A Patch Test Might Tell You - Allure - August 29th, 2022 [August 29th, 2022]
- Stinky sweat turns out to have a surprising health benefit : Goats and Soda - NPR - August 29th, 2022 [August 29th, 2022]
- Makeup for Eczema-Prone Skin: Considerations, Products, and Tips - Healthline - July 13th, 2022 [July 13th, 2022]
- Eczema Vaccinatum: Symptoms, Diagnosis, and Treatment - Healthline - July 13th, 2022 [July 13th, 2022]
- What Is Topical Steroid Withdrawal in Atopic Dermatitis Treatment? - Everyday Health - July 13th, 2022 [July 13th, 2022]
- A new 'cure for eczema' pill has been signed off but who is allowed to take it? - Cosmopolitan UK - July 13th, 2022 [July 13th, 2022]
- What Causes Dandruff And How To Get Rid Of It, According To A Dermatologist - Fatherly - July 13th, 2022 [July 13th, 2022]
- Allergies on the rise due to climate change - BusinessWorld Online - July 13th, 2022 [July 13th, 2022]
- Cryotherapy Treatment: Uses and Benefits - newschannelnebraska.com - July 13th, 2022 [July 13th, 2022]
- Mutations of Filaggrin Leading to Eggs & Milk Allergies - Physician's Weekly - June 18th, 2022 [June 18th, 2022]
- How AI & the Pandemic Are Changing the Skin & Hair Clinic Experience - The Quint FIT - June 18th, 2022 [June 18th, 2022]
- How to treat your childs dry skin in winter - Lowvelder - June 15th, 2022 [June 15th, 2022]
- Topical steroid: Types, uses, side effects and treatment as revealed by doctors - Hindustan Times - June 15th, 2022 [June 15th, 2022]
- Psoriasis in the Belly Button: Symptoms, Causes, and Treatment - Healthline - June 15th, 2022 [June 15th, 2022]
- In his last days, my father asked for Yiddish music - Forward - June 15th, 2022 [June 15th, 2022]
- Throwing away the water after cooking rice? Know how it could benefit your skin and hair - Times Now - June 15th, 2022 [June 15th, 2022]
- Family 'devastated and numb' as boy, 9, dies a day after breaking his arm - Coventry Live - June 15th, 2022 [June 15th, 2022]
- Happy Cappy Not Just For Babies; Everyone With Sensitive Skin Can Benefit - Pediatric Shampoo Granted Trademark in New Campaign: 'No Scalp Left... - June 15th, 2022 [June 15th, 2022]
- Eczema on black skin: Pictures, symptoms, and treatment - June 11th, 2022 [June 11th, 2022]
- Eczema on the Ears or Eyebrows: How to Cope - Everyday Health - June 11th, 2022 [June 11th, 2022]
- What People With Eczema Need to Know About Self-Screening for Skin Cancer - National Eczema Association - June 11th, 2022 [June 11th, 2022]
- How to protect children with eczema from scratching until they bleed - Channel NewsAsia - June 11th, 2022 [June 11th, 2022]
- Autism, allergies and other diseases and disorders afflicted baby boomers, too - PolitiFact - June 11th, 2022 [June 11th, 2022]
- Is saltwater good for the skin? What to know Beaufort South Carolina The Island News - The Island News - June 11th, 2022 [June 11th, 2022]
- What's trending? The most-read stories on APAC beauty market and consumer insights - CosmeticsDesign-Asia.com - June 11th, 2022 [June 11th, 2022]
- Canada to require a warning be printed on every cigarette - Coventry Live - June 11th, 2022 [June 11th, 2022]
- Holistic Acne Treatments That Are Better Than What You've Been Doing - The List - June 11th, 2022 [June 11th, 2022]
- Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials - PR Newswire UK - June 7th, 2022 [June 7th, 2022]
- Woman left balding and bedbound by chronic eczema clears the condition with a 9 face cream - The Independent - June 7th, 2022 [June 7th, 2022]
- Poll: Six in 10 people would eat food that has fallen on the floor - Coventry Live - June 7th, 2022 [June 7th, 2022]
- The itch that rashes: Treating and understanding eczema - El Paso Inc. - June 5th, 2022 [June 5th, 2022]
- Celebrities With Eczema Speak Out - Everyday Health - June 5th, 2022 [June 5th, 2022]
- Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema - HealthDay News - June 5th, 2022 [June 5th, 2022]
- Antibiotics Given Before C-sections Are Not Linked to Asthma, Eczema in Young Children - Pharmacy Times - June 5th, 2022 [June 5th, 2022]
- Eczema Skin-Care Products Market Size, Scope and Forecast | Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and... - June 5th, 2022 [June 5th, 2022]
- What are the benefits of ceramides for the skin? - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Some Allergies Associated With Lower Risk of SARS-CoV-2 Infection - Smithsonian Magazine - June 5th, 2022 [June 5th, 2022]
- The CDC is sending monkeypox vaccines to people at high risk in a race to prevent the spread - CNBC - June 5th, 2022 [June 5th, 2022]
- Missing Sikeston teen may be heading to Kansas City area - KMBC Kansas City - June 5th, 2022 [June 5th, 2022]
- Should you cleanse or exfoliate first? What to know - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Dry Skin: Eczema, Itchy Skin, Causes, Treatments, Relief, Types - May 17th, 2022 [May 17th, 2022]
- Foods to Eat and Foods to Avoid If You Have Eczema - The Beet - May 17th, 2022 [May 17th, 2022]
- 3 Women With Eczema Describe the Ways They Combat Nighttime Flare-Ups - Verve Times - May 17th, 2022 [May 17th, 2022]
- The Challenges of Parenting a Child With Eczema - Verve Times - May 17th, 2022 [May 17th, 2022]
- Manuka Honey Benefits for Skin: Benefits, Masks, and More - Greatist - May 17th, 2022 [May 17th, 2022]